Cost-Effectiveness of Fecal Immunochemical Testing Alone vs Co-Testing With Stool Antigen
JAMA 10.1001/jama.2026.6908June 01, 2026 at 11:00 AM EDT
Among individuals invited to undergoing colorectal cancer screening with a fecal immunochemical test (FIT), is the addition of a stool antigen test cost-effective compared with FIT alone?In this economic evaluation based on a randomized clinical trial involving 240 000 individuals, invitation to co-testing for stool antigen in addition to FIT was cost-saving in 65.7% of 100 000 probabilistic simulations and cost-effective in the remaining 34.3% compared with FIT alone.In a pragmatic randomized comparison of invitation strategies, inviting individuals to undergo combined stool antigen testing and FIT was more cost-effective than inviting FIT alone when evaluated under real-world conditions with incomplete adherence.
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.